Egypt Medical Device Regulatory Framework: The Three-Tier Legal Structure

1. Key takeaways

Egypt regulates medical devices through a three-tier structure, and no single tier can be skipped when assessing any requirement. The first tier is Law No. 151/2019, which establishes the Egyptian Drug Authority (EDA) and is the source of regulatory authority. The second tier is Prime Minister Decree 777/2020, the executive regulation of that law, which simultaneously serves as the basis for fees. The third tier consists of the EDREX series of guidelines issued by the EDA, which prescribe the concrete procedures and document lists for registration, import approval, changes, and vigilance. For companies, the operative basis in day-to-day work sits in the third tier, yet without a firm grasp of the first two tiers it is impossible to judge whether any given requirement actually has a statutory foundation. A requirement found only in a guideline is still binding in practice, but knowing exactly where it comes from determines how confidently it can be defended, challenged, or budgeted for. Any dossier decision should therefore be traceable upward through all three tiers before it is executed.

2. Legal basis

Read together, these instruments form a closed chain of authority: the law creates the regulator, the decree operationalizes it and fixes the fee categories, and the two EDREX guidelines translate both into the registration and import-approval workflows that companies actually experience. Any clause in a dossier template, service contract, or internal SOP should be traceable back to one of these rows before it is treated as a firm requirement.

3. Expert insights

Insight 1: the three tiers are not a simple stack of superior and subordinate rules, but a transmission chain running from authorization to elaboration to operation.

Law No. 151/2019 entrusts the registration, circulation, and supervision of medical devices to the EDA, but it does not prescribe how many documents a dossier must contain. Prime Minister Decree 777/2020 converts the law into an executable regulation, of which the most important element for planning purposes is the fee schedule categories. The EDREX guidelines then bring the decree down to operational nodes such as acceptance within 5 working days and evaluation within 20 working days. The practical consequence is that a guideline revision does not amend the law, yet it can immediately change how a company files, what it pays, and how it budgets. Compliance teams should treat guideline updates as first-order regulatory events rather than administrative housekeeping, because every downstream step depends on them.

Insight 2: the fee basis is dual-track, combining the executive regulation and the EDA Chairman’s decision, a point frequently misread as the EDA setting prices on its own.

Section 4.1.1 of EDREX: GL.CAMD.002 states that registration application fees are charged according to the fee schedule categories set out in Prime Minister Decree 777/2020, the executive regulation of the law establishing the EDA, while service fees are charged according to the decisions issued by the EDA Chairman in that regard. The two fee components therefore come from norms at different hierarchical levels: the fee categories from the decree, and the service fees from the Chairman’s decision. (Practical estimate: the specific amounts in Egyptian pounds must be taken from the payment notice generated by the MeDevice platform and from the current EDA Chairman’s decision.) Companies that budget from a single blended figure risk understating one component whenever either instrument is updated, so the two streams should be modelled separately.

Insight 3: the concentrated guideline version change in September 2025 is the trigger for this round of compliance review.

GL.CAMD.002, GL.CAMD.09, GL.CAMD.007, and GL.CAMD.008 were upgraded to Version 2, and GL.CAMD.003 to Version 3, all effective in September 2025, while the vigilance guideline GL.CAP.Care.040 was first published in November 2025. Dossiers, templates, and SOPs compiled on the basis of the 2024 and earlier versions must be re-verified against the current versions before any new submission. Because fee citations, document lists, and acceptance nodes all live in the guidelines, a stale version reference can invalidate an otherwise complete application. A version audit across the entire EDREX library should therefore precede any submission planned after September 2025, and the audit result should be recorded in the regulatory file.

Insight 4: the legal tier is nearly static while the guideline tier changes frequently, and monitoring resources should be allocated accordingly.

Law No. 151/2019 has not undergone any fundamental amendment since its publication in 2019. Change has concentrated at the guideline and announcement levels, exemplified by the April 16, 2026 announcement simplifying requirements for local factories. A regulatory intelligence mechanism should therefore monitor the EDA website’s publication library and announcement board at high frequency while reviewing the statutory texts at low frequency. Allocating effort the other way around produces teams that know the law precisely but file dossiers under superseded procedures, which is the most expensive kind of knowledge gap in this market.

4. Practical recommendations

1. Maintain a three-tier document register: record the number, version, effective date, and applicable stage of the law, the executive regulation, and each EDREX guideline separately, so every procedural claim can be traced to its source.
2. Account for fee schedule categories and service fees separately: the former follow Prime Minister Decree 777/2020 and the latter follow the EDA Chairman’s decision, so they should never be merged into one budget line.
3. Set version-trigger rules: any version change to an EDREX guideline triggers a review of dossiers, SOPs, and budget, with the review outcome logged and signed off.
4. Cite all three tiers in external references: when reporting to clients or management, avoid saying only that the EDA requires something; give the law, the regulation, and the guideline clause numbers.
5. Treat the MeDevice payment notice as the final basis for amounts: follow the payment voucher generated by the platform rather than historical experience values, since the current Chairman’s decision controls the service-fee component.

5. Verification checklist

• □ Confirmed the three-tier structure: law, executive regulation, EDREX guidelines
• □ Recorded the publication date of Law No. 151/2019 as August 25, 2019
• □ Recorded Prime Minister Decree 777/2020 as the basis for fee categories
• □ Checked the current versions and effective dates of the relevant EDREX guidelines
• □ Established a rule under which guideline version changes trigger a review
• □ Confirmed amounts against the MeDevice payment notice (practical estimate review)

Regulatory information verified as of October 29, 2026. The three-tier structure described in this article is subject to the official texts of Law No. 151/2019, Prime Minister Decree 777/2020, and the current EDREX guidelines issued by the EDA; when guidelines are revised or a new executive regulation is issued, the content must be re-checked.

• Local Egypt support: GRZAN assists manufacturers from the Chinese mainland and overseas with medical device registration, import approval, and change applications before the Egyptian Drug Authority (EDA), including design of the registration applicant structure (importing company, local factory, or scientific office), preparation for Scientific Committee evaluation, advisory work on pathways for obtaining free sale certificates from reference countries, Arabic localization of labels and instructions for use, and the build-out of vigilance systems and periodic reporting.
• Service capabilities: product characterization and risk classification (devices Class I–III and IVDs Class A–D), registration and re-registration, determination of applicability of system registration and group registration, three-category determination of changes, import approval and annual import plans, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.